Continuous Improvement Manager

Waters Corporation appoints Bharath Raju Chinnathambi as India Communications Lead. He is the first communications employee in the India region to lead communications for both the India market and the Waters GCC. Waters Corporation has appointed Bharath Raju Chinnathambi as India Communications Lead, with the communications mandate covering both the India market and the company's Global Capability Centre (GCC). The appointment marks a significant communications expansion for Waters in India, with Chinnathambi becoming the first communications employee in the region. He will be tasked with building the communications ecosystem for India and the GCC from the ground up, working closely with global, India and GCC leadership teams, media partners and internal stakeholders. He will focus on strengthening brand affinity, developing integrated narratives and showcasing the work across Waters' India ecosystem, while also shaping and protecting the company's corporate reputation. Announcing the move on LinkedIn, Chinnathambi said, "I'm excited to share that I've joined Waters Corporation as India Communications Lead, stepping in as the first communications employee in the India region to lead communications for both the India market and the Waters GCC! Being trusted to build the communications ecosystem from the ground up for an enterprise at the absolute forefront of scientific precision is an absolute honour." He added, "In this role, I'll be working closely with our global, India and GCC leadership teams, media partners, and talented colleagues to elevate our brand affinity, drive integrated narratives, and showcase the incredible work happening across our Waters ecosystem." He joins Waters from Sanofi, where he most recently served as Global Hub Senior Communications & Engagement Partner. Prior to that, he spent over three years with Bosch India. With experience spanning internal and external communications, brand management, employee engagement and strategic storytelling, he will now lead Waters' communications efforts across its India market and GCC. For more updates, be socially connected with Badshah Masala on Instagram, LinkedIn, Twitter, Facebook YouTube & Google News Published On: Sep 16, 2026 9:00 AM

Everlywell announces a partnership with Waters Corporation to bring the most comprehensive fda-cleared at-home HPV cervical Cancer Screening tool available in the U.S. Today to patients. New partnership delivers a diagnostics-led care that helps plans engage eligible members and connect women to appropriate follow-up care, consultation, and in-person referrals AUSTIN, Texas-(BUSINESS WIRE)-Everlywell, a leader in digital health, today announced a partnership with Waters Corporation to ensure patients have access to the most comprehensive at-home HPV cervical cancer screening tool available in the U.S. today, the Onclarity(TM) HPV Self-Collection Kit, tested with the BD Onclarity(TM) HPV Assay.[1] The new diagnostic-led solution supports health plans as they expand access to cervical cancer screening and make it easier for eligible members to complete recommended preventive care. "Every woman deserves a clear and accessible path to understand her health and take the next right step. The new partnership expands access to screening, and connects women to appropriate follow-up care." Share The American Cancer Society estimates that over 13,000 new invasive cervical-cancer cases will be diagnosed in the U.S. this year.[2] While screening and HPV vaccination have improved diagnosis over time, screening gaps remain substantial, with one in four women not up to date in testing. In fact, roughly half of women diagnosed with cervical cancer have never been screened or are overdue for a test. However, these cancers rarely occur in women who have been getting regular tests to screen for cervical cancer before the age of 65.[2] Members can collect the sample at home and send it back to a CLIA-certified laboratory. Results are delivered digitally through the Everlywell platform, and clinical follow-up is available via telehealth consultation, with in-person referral for further evaluation for members with abnormal results. "Every woman deserves a clear and accessible path to understand her health and take the next right step. The new partnership expands access to screening, and connects women to appropriate follow-up care," said Julia Cheek, Founder and CEO of Everlywell. "By bringing together outreach, convenient screening access, clinician-guided results, and connected care systems, we can help plans close care-gaps while preparing for the next generation of women's preventive care." Everlywell is among the first to market with an FDA-cleared, at-home HPV testing solution in direct response to the NCQA MY2026 update. Cervical Cancer Screening-Electronic Clinical Data Systems (CCS-E) remains one of the more difficult preventive screening measures to improve because traditional screening requires an in-person visit. At-home testing expands access to members who are overdue, difficult to reach, or reluctant to complete in-office screening. By connecting screening activity with care pathways, the solution is designed to help plans address CCS-E care gaps, and prepare for updated federal preventive-services guidance taking effect in 2027. Everlywell's HPV Test is part of the platform's broader effort to expand access to cancer screening, women's health insights and preventive care. Everlywell's consumer and enterprise offerings span a variety of cancer screenings, cardiometabolic screenings, fertility-related testing, hormone and thyroid biomarkers, and sexual-health testing, with results designed to help eligible individuals understand their information and pursue appropriate medical follow-up when needed. The Onclarity(TM) HPV Self-Collection Kit is tested with the BD Onclarity(TM) HPV Assay, which detects 14 high-risk HPV genotypes to identify oncogenic risk and is the only FDA-approved HPV assay to identify six individual genotypes and three groups of pooled results, making it the most comprehensive HPV screening tool available in the U.S. today.[1] For more than a decade, Everlywell has pioneered direct empowerment of consumers and health plan members to take control of their own health, combining AI-powered technology with human insight, advanced diagnostics, virtual care, and patient engagement to help people better understand their health and take informed and actionable next steps. To learn more about Everlywell and access to the Onclarity(TM) HPV Self-Collection Kit, visit https://www.everlywell.com/enterprise. About Everlywell Everlywell is a digital health company transforming complex biomarker data into life-changing insights - seamlessly integrating advanced diagnostics, virtual care, and patient engagement to expand access, close care gaps, and improve health outcomes across the full care journey. Through at-home and clinician-supported testing and virtual care experiences, Everlywell empowers individuals with the information they need to make more informed health decisions. Over the past decade, Everlywell has delivered nearly one billion personalized health insights, transformed care for 60 million people and powered hundreds of enterprise partners, including four of the top five largest health plans in the U.S. that cover 170 million insured lives. In 2025 alone, an estimated one in 94 U.S. households received an Everlywell test, solidifying its spot as the #1 at-home testing brand in the country. Fueled by AI and built for scale, Everlywell is breaking down barriers, closing care gaps, and unlocking a more connected healthcare experience that is smarter, faster, and more personalized. Learn more at everlywell.com. Disclaimer: The BD Biosciences and BD Diagnostic Solutions businesses have been acquired by Waters Corporation ("Waters"). Becton, Dickinson and Company or one of its affiliates or subsidiaries ("BD") remains the legal manufacturer of Biosciences and Diagnostic Solutions products until all required regulatory transfers are completed. During this interim period, BD maintains full responsibility for all regulatory obligations of the legal manufacturer. Product information provided here is supplied under BD's regulatory authority. To learn more about the relationship between Waters and BD during this transition period, please see our detailed summary: www.waters.com/bdtransaction. [1] There are currently two FDA-approved HPV tests with extended genotyping with different configurations. The BD Onclarity(TM) HPV Assay individually identifies 6 high-risk HPV genotypes and strategically groups 3 results for 8 moderate-risk HPV genotypes. [2] https://www.cancer.org/cancer/types/cervical-cancer/about/key-statistics.html More News From Everlywell AUSTIN, Texas-( BUSINESS WIRE )-Everlywell, a leader in digital health, today reported new insights from Eva Engage, the personalized outreach capability within Eva, its AI health companion launched earlier this year. Eva is powered by three core engines, Eva Engage, Eva Care, and Eva Support, that create an intelligent, connected care experience, helping individuals take meaningful action for their health. Eva Engage is more proactive, timely, and deeply personal than traditional outreach. Its... AUSTIN, Texas-( BUSINESS WIRE )-Everlywell, a leader in digital health, today announced the launch of Eva - an AI-powered platform that turns complex biomarker data into easy-to-understand, personalized health insights. Eva combines intelligence with engaging tools to guide and motivate individuals to take meaningful action for their health. Eva is an intelligent health companion that helps personalize crucial touchpoints with smart recommendations and insights throughout the healthcare journey,... RESEARCH TRIANGLE PARK, N.C.-( BUSINESS WIRE )-The American Sexual Health Association (ASHA), America's nonprofit authority for sexual health information, is launching its inaugural National Get Tested Day on September 30 to advance the conversation around sexual health and break down barriers to accessing this essential health care. On the launch of National Get Tested Day, ASHA is partnering with Everlywell, a leader in at-home STI lab testing and treatment, to give away 250 free Everlywell a... Everlywell. Release Versions

Waters Corporation has launched the BD FACSDiscover A7 Cell Analyzer globally, expanding its flow cytometry platform. The instrument combines spectral resolution and sensitivity with standardisation features, making advanced flow cytometry more accessible to researchers in academic, pharmaceutical, and contract research settings. The analyzer incorporates BD SpectralFX Technology, enabling scientists to analyse more than 50 characteristics of a single cell. Its FACSTruQ Technology delivers automated setup and quality control, providing data consistency across instruments with less than 10% coefficient of variation across more than 50 dyes. Steve Conly, Senior Vice President at Waters Biosciences, said the A7 offers "a compelling price-to-performance balance," extending spectral flow cytometry capabilities developed two years ago when the world's first 50-colour flow cytometry panel was created. The analyzer is now available to order through local representatives.